# US 2025/0019428 A1 · Manufacturing Methods for Producing Anti-TNF Antibody Compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0019428 A1
- Document ID: US20250019428A1
- Status: Published application
- Kind: A1
- Application number: 18/765,711
- Filed: 2024-07-08
- Published: 2025-01-16
- Earliest claimed: 2019-03-14
- Assignees: Janssen Biotech, Inc.
- Applicants: Janssen Biotech, Inc.
- Inventors: Kristopher Barnthouse; Subinay Ganguly; Maarten Groeneveld; Manuel Lopez, JR.; Michael Nedved; Kevin D. Smith
- Web page: https://patentgrep.com/patent/US20250019428A1

## CPC

- C07K 16/241: {Tumor Necrosis Factors}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/21: from primates, e.g. man
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods of manufacture for producing anti-TNF antibodies, e.g., the anti-TNF antibody a recombinant anti-TNF antibody having a heavy chain (HC) comprising amino acid sequence SEQ ID NO:36 and a light chain (LC) comprising amino acid sequence SEQ ID NO:37 and compositions comprising the recombinant anti-TNF antibody.

## Claims

### Claim 1

Anti-TNF antibodies comprising: a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 2, a HC CDR3 comprising the amino acid sequence of SEQ ID NO:3, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 6, wherein the oligosaccharide profile of the anti-TNF antibodies comprises:
a) total neutral oligosaccharide species >99.0%;
b) total charged oligosaccharide species <1.0%;
c) individual neutral oligosaccharide species G0F>60.0%;
d) individual neutral oligosaccharide species G1F<20.0%; or
e) individual neutral oligosaccharide species G2F<5.0%.

### Claim 2 (depends on 1)

The anti-TNF antibodies of claim 1, wherein the oligosaccharide profile of the anti-TNF antibodies comprises total neutral oligosaccharide species >99.0% and total charged oligosaccharide species <1.0%.

### Claim 3 (depends on 1)

The anti-TNF antibodies of claim 1, wherein the oligosaccharide profile of the anti-TNF antibodies further comprises individual neutral oligosaccharide species G0F>60.0%, G1F<20.0%, and G2F<5.0%.

### Claim 4 (depends on 1)

The anti-TNF antibodies of claim 1, wherein the anti-TNF antibodies have no disialylated glycan species as determined by High Performance Liquid Chromatography (HPLC) or Reduced Mass Analysis (RMA).

### Claim 5 (depends on 1)

The anti-TNF antibodies of claim 1, wherein the anti-TNF antibodies have a longer half-life or increased antibody-dependent cell-mediated cytotoxicity (ADCC) compared to anti-TNF antibodies expressed in Sp2/0 cells.

### Claim 6 (depends on 5)

The anti-TNF antibodies of claim 5, wherein the anti-TNF antibodies are a follow-on biologic.

### Claim 7

A method of manufacture for producing anti-TNF antibodies comprising: a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 2, a HC CDR3 comprising the amino acid sequence of SEQ ID NO:3, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 6, wherein the anti-TNF antibodies are produced by a method of manufacture comprising:
a. culturing Chinese Hamster Ovary cells (CHO cells), wherein the CHO cells comprise a nucleic acid encoding the anti-TNF antibodies;
b. expressing the anti-TNF antibodies in the CHO cells; and,
c. purifying the anti-TNF antibodies,
wherein the oligosaccharide profile of the anti-TNF antibodies comprises:
a) total neutral oligosaccharide species >99.0%;
b) total charged oligosaccharide species <1.0%;
c) individual neutral oligosaccharide species G0F>60.0%;
d. individual neutral oligosaccharide species G1F<20.0%; or
e. individual neutral oligosaccharide species G2F<5.0%.

### Claim 8 (depends on 7)

The method of manufacture of claim 7, wherein the oligosaccharide profile of the anti-TNF antibodies comprises total neutral oligosaccharide species >99.0% and total charged oligosaccharide species <1.0%.

### Claim 9 (depends on 7)

The method of manufacture of claim 7, wherein the oligosaccharide profile of the anti-TNF antibodies further comprises individual neutral oligosaccharide species G0F>60.0%, G1F<20.0%, and G2F<5.0%.

### Claim 10 (depends on 7)

The method of manufacture of claim 7, wherein the anti-TNF antibodies have no disialylated glycan species as determined by High Performance Liquid Chromatography (HPLC) or Reduced Mass Analysis (RMA).

### Claim 11 (depends on 7)

The method of manufacture of claim 7, wherein the anti-TNF antibodies have a longer half-life or increased antibody-dependent cell-mediated cytotoxicity (ADCC) compared to anti-TNF antibodies expressed in Sp2/0 cells.

### Claim 12 (depends on 11)

The method of manufacture of claim 11, wherein the anti-TNF antibodies are a follow-on biologic.

### Claim 13

A composition comprising anti-TNF antibodies: a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 2, a HC CDR3 comprising the amino acid sequence of SEQ ID NO:3, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 6, wherein the oligosaccharide profile of the anti-TNF antibodies comprises:
a) total neutral oligosaccharide species >99.0%;
b) total charged oligosaccharide species <1.0%;
c) individual neutral oligosaccharide species G0F>60.0%;
d) individual neutral oligosaccharide species G1F<20.0%; or
e) individual neutral oligosaccharide species G2F<5.0%.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the oligosaccharide profile of the anti-TNF antibodies comprises total neutral oligosaccharide species >99.0% and total charged oligosaccharide species <1.0%.

### Claim 15 (depends on 13)

The composition of claim 13, wherein the oligosaccharide profile of the anti-TNF antibodies further comprises individual neutral oligosaccharide species G0F>60.0%, G1F<20.0%, and G2F<5.0%.

### Claim 16 (depends on 13)

The composition of claim 13, wherein the anti-TNF antibodies have no disialylated glycan species as determined by High Performance Liquid Chromatography (HPLC).

### Claim 17 (depends on 13)

The composition of claim 13, wherein the anti-TNF antibodies have a longer half-life or increased antibody-dependent cell-mediated cytotoxicity (ADCC) compared to anti-TNF antibodies expressed in Sp2/0 cells.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the anti-TNF antibodies are a follow-on biologic.
